Influence of Short-term Intensive Insulin Therapy on Expression of TLR4, lL-6, and IL-lβ in Peripheral Blood Mononuclear Cells of Patients with Type-2 Diabetes Mellitus
LIAO Zhou-yi, ZHENG Hao-tian, FENG Yi , et al
Hemodialysis Center, Department of Nephrology, West China Hospital, Sichuan University , Sichuan Chengdu 610041
Abstract：【Objective】To explore the influence of short-term intensive insulin therapy (CSII) on toll like receptor-4 (TLR4), interleukin-6 (lL-6), and interleukin-lβ (IL-lβ) expressions in peripheral blood mononuclear cells of patients with type-2 diabetes mellitus (T2DM). 【Methods】A total of 86 cases of patients with T2DM treated in our hospital were selected as the observation group, and 80 cases of healthy volunteers with normal physical examination were selected as the control group. The observation group were given CSII treatment for two weeks. Clinical data such as the peripheral blood glucose (FPG), postprandial 2h blood glucose (2hPG), insulin resistance index (HOMA-IR), triglyceride (TG), total cholesterol (TC), glycosylated hemoglobin (HbAlc) were measured before and after treatment in the observation group. High Density Lipoprotein (HDC-L), Low Density (LDC-L)/High Density Lipoprotein (HDC-L) of the two groups before and after treatment were measured, and TLR4, lL-6, and IL-lβ levels were detected by using reverse transcription polymerase chain reaction (RT-PCR) as well.【Results】After treatment, FPG, 2hPG, HOMA-IR, TG, TC, and HbAlc were all lower than those before the treatment, and the differences were statistically significant (P<0.05). However, compared to the control group, FPG, 2hPG, HOMA-IR, TG, TC, HbAlc levels did not change significantly after treatment (P>0.05). The results of RT-PCR showed that the expressions of TLR4, IL-l beta and lL-6 mRNA in peripheral blood mononuclear cells after treatment were lower than those before treatment (P<0.05);however, compared to the control group, the difference was not significant (P>0.05). 【Conclusion】Short-term intensive insulin therapy (CSII) in the treatment of patients with T2DM can control blood sugar (glucose) and increase insulin sensitivity. It may be related to the inhibition of TLR4, lL-6, and IL-lβ expressions in peripheral blood mononuclear cells.
2018, Vol. 35 
